Diabetes and hypertension will become increasingly common as the population becomes older and more obese. Together, they markedly increase cardiovascular and renal damage, placing all diabetic hypertensives at high risk. Fortunately, the appropriate use of lifestyle
Introduction
Hypertension and diabetes frequently coexist, in large part from underlying obesity. Among all diabetics, hypertension is found in over 70%.
When the two coexist, cardiovascular-renal complications occur at a much higher rate, at least twofold overall and many-fold for progressive nephropathy. There may be an obvious explanation for some of the increased prevalence of hypertension, nephropathy and diabetes: hyperglycaemia during pregnancy reduces nephrogenesis in the fetus. 1 Just as maternal protein deprivation leads to a reduced number of nephrons, so could hyperglycaemia. The infants of women with abnormal glucose tolerance or overt diabetes would then be susceptible to more hypertension, diabetes and nephropathy.
In addition there are multiple reasons for the increasing prevalence of diabetes and hypertension. These include: the advancing age of the population; increasing prevalence of obesity plus physical inactivity; the rapid growth of more susceptible populations including Hispanics and African-Americans; the prolonged survival of type I diabetics; and the expanding reach of medical care.
The predominant role of obesity
The current US population is likely the fattest of all time. Obesity, defined as a body mass index (BMI) 30 kg/m 2 , increased from 12% of US adults in 1991 to 17.9% in 1998. 2 The increase occurred in virtually every part of the population. Similar increases in the prevalence of obesity is occurring in other developed societies and obesity is increasing rapidly as less-developed societies adopt western lifestyles with more caloric intake and less physical activity.
With increasing BMI, type 2 diabetes increases markedly. 4 A 5-kg weight gain doubles the risk for diabetes and the risk increases with the duration of excess weight. Not surprisingly, cardiovascular mortality is increased with increasing BMI. About 300 000 annual deaths are attributable to obesity in the US.
Since prevention of weight gain in adults is difficult and loss of excess weight even more difficult, the best solution is to prevent obesity in children by keeping them physically active, mainly by turning off the TV (and the computer).
Non-pharmacological therapy
Therapy for all hypertension should begin and continue with lifestyle modifications, even more so in the typically obese type 2 diabetic. However, the high risk of premature cardiovascular disease in even diet-controllable type 2 diabetes almost mandates early and intensive antihypertensive therapy as well. The regimens should include:
Weight loss: Weight loss lowers blood pressure at least in part by improving insulin sensitivity, Exercise: Those who are sedentary and unfit develop more diabetes whether lean or obese. 5 The benefits of exercise in patients with diabetes include improvement in glycaemic control, lowering of blood pressure, reduction in levels of triglyceriderich low-density lipoproteins, probable improvement in fibrinolytic activity, and reduction in cardiovascular disease,
Moderate sodium reduction:
Moderate sodium reduction is both safe and effective, 6 perhaps even more in those diabetics whose hypertension is related to volume expansion from the renal impairment of nephropathy, Moderate alcohol consumption: Diabetics have been found to obtain a protective effect against cor-onary disease by regular moderate alcohol consumption (no more than two drinks a day) similar to that seen in multiple other groups. 7 Cessation of smoking: As the most important lifestyle to be addressed, smoking may markedly aggravate insulin resistance in type 2 diabetics.
Antihypertensive drug therapy
The best documentation of the need to lower diastolic blood pressure to or below 80 mm Hg comes from the Hypertension Optimal Treatment (HOT) trial. 8 Among the 1501 diabetic hypertensives, a greater than 50% reduction in the incidence of major cardiovascular events occurred in those whose target diastolic blood pressure was 80 mm Hg or lower compared with those whose target pressure was 90 mm Hg or lower. As in the HOT trial, to achieve the necessary goal of blood pressure of less than 130/80 mm Hg will usually require two or more antihypertensive drugs.
To provide the other essential corrections for concomitant risk factors, multiple non-drug and drug therapies will be needed. The benefits of such intensive therapy are impressive, as shown in a trial of 160 diabetics with microalbuminuria who were randomly allocated to standard therapy or more intensive therapy. 9 Those given more intensive therapy to achieve lower levels of blood pressure, glycaemic control and lipid levels were also routinely given angiotensin-converting enzyme (ACE) inhibitors, aspirin, diet and exercise. At the end of 3.8 years, those on more intensive therapy had 70% reductions in the rates of progression of nephropathy, retinopathy and autonomic neuropathy compared with those left on standard therapy. Clearly, though such intensive therapy is troublesome and costly, it would not only reduce morbidity and mortality but also lower lifetime medical costs.
Antihypertensive drugs
For those without proteinuria, a low-dose diuretic may be the appropriate first choice with an ACE inhibitor (ACEI) as second drug and a long-acting calcium antagonist (CA) as third. Both beta-blockers and alpha-blockers may be indicated. Rarely, central ␣ 2 -agonists may be useful. For those with proteinuria, an ACEI is mandatory. An ALL receptor blocker (ARB) should be substituted if a cough precludes use of an ACEI.
Diuretics: Low doses, ie 12.5 mg of hydrochlorothiazide, are effective and safe in diabetics as shown in multiple trials. 10 A thiazide diuretic should be almost always included in the regimen and loop diuretics given only to those with serum creatinine above 1.5 mg/dl.
Beta-blockers:
Despite many warnings about their potential to aggravate diabetes in various ways, betaJournal of Human Hypertension blockers are effective and safe. They are mandatory for those who survive a myocardial infarction. Since they were somewhat more protective than an ACEI in the UKPDS trial, 11 their use may increase.
Alpha-blockers:
In addition to their ability to relieve prostatism, alpha-blockers are better than any other class in reducing insulin resistance and improving dyslipidaemia.
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Calcium antagonists: Concerns persist about the safety of CAs, particularly the dihydropyridines (DHP) and particularly in diabetic hypertensives. As to their putative effect to increase coronary disease, the problem remains unique to large doses of shortacting agents. 13 As to their particular effects in diabetes, much of the current evidence of benefit from antihypertensive therapy in diabetics comes from trials using DHP-CAs.
Therefore, the use of long-acting CAs in diabetics can be defended for the following reasons:
(1) the excellent protection found in Syst-Eur with nitrendipine, even better than that found in a similar group of hypertensive diabetics given a diuretic in the SHEP trial;
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(2) the major reduction in cardiovascular events in the 1501 diabetics given felodipine-based therapy in the HOT trial; 8 and (3) the lack of significant adverse effects in the amlodipine quarter of the ongoing ALLHAT trial with over 15 000 diabetics enrolled.
The bottom line, at present, indicates that either DHP-CAs or nonDHP-CAs are frequently needed to control the hypertension in most diabetics, particularly to prevent the progression of renal damage. They may be renoprotective even if they do not reduce proteinuria as well as seen with ACE inhibitors. 15 ACEIs: An ACEI should always be used for those with proteinuria. This likely should be expended to normotensive diabetics with microalbuminuria: over 4 years, nine of 23 such patients on placebo advanced to diabetic nephropathy, whereas only two of 21 given captopril advanced. 16 Whether an ACEI should also be the routine first drug for all diabetics without microalbuminuria is less certain but looking more and more likely. In the Captopril Prevention Project (CAPPP), those diabetics given captopril had fewer events than did those given diuretics and beta-blockers whereas there was no difference in the non-diabetics. 17 On the other hand, the ACEI was somewhat less protective than the beta-blocker in the UKPDS trial involving type 2 diabetic hypertensives. 11 The benefits may have simply reflected their lower blood pressure.
In the Heart Outcomes Prevention Evaluation (HOPE) trial, the 9297 patients with known cardiovascular disease included 38% with diabetes; over
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Journal of Human Hypertension the 4 -6 year follow-up, a 17% risk reduction for diabetic complications was reported for those given the ACEI ramapril compared to those assigned to placebo. 18 
Angiotensin receptor blockers (ARBs):
For the 10% of patients given an ACEI who develop a cough, an ARB is a logical alternative. Their more widespread usage is not recommended in any of the recent guidelines but they are being widely promoted for initial therapy. Six ARBs are now approved in the US for hypertension. They seem equipotent and equally free of side effects, although angioedema has been noted. Losartan appears to be unique in having a modest uricosuric effect. ARBs reverse left ventricular hypertrophy and diminish proteinuria. The first published outcome study (ELITE I) suggested a better effect of losartan than captopril in heart failure. 19 However, the larger follow-up trial (ELITE II) found no statistically significant difference, but a somewhat more favourable effect with captopril. 20 A large number of outcome trials are in progress with all of the available ARBs.
Are there meaningful clinical differences between ACEIs and ARBs? For now the answer is no. In a diabetic rat model, losartan and captopril had comparable effects on reducing proteinuria, possibly through different mechanisms involving basement membrane anionic charges. An ARB was reported to cause less of a rise in serum potassium than an ACEI in patients with nephropathy. 21 Both agents had similar effects on reducing blood pressure and proteinuria.
Since the two classes have different effects on various parts of the rennin-angiotensin system, an additive effect may occur. Preliminary evidence has been reported for additive effects on lowering blood pressure by the combination of low doses of lisinopril and losartan.
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Diabetic nephropathy
Now the most common cause of end-stage renal disease (ESRD) in the western world and likely to become even more common as diabetes begins earlier and lasts longer, nephropathy has been well characterised as a common complication after 15 years of diabetes, leading to renal failure within 5 years in over half who develop proteinuria. Fortunately, its progression can be stopped 23 (Table 1 ). Blood pressure and proteinuria can be reduced in parallel. Two issues need to be considered.
First, the goal of therapy. Calcium antagonists are less effective in reducing proteinuria and short-acting formulations have increased proteinuria. 26 Long-acting formulations including verapamil, diltiazem, the dihydropyridines amlodipine and nitrendipine have been found to be similar to ACEIs. 15, 27 However, more protection against myocardial infarction was noted among those diabetics initially given enalapril than those initially given nisoldipine. 28 Most patients will likely end up needing the combination of an ACEI and a CA to lower blood pressure to below 130/80 mm Hg and the combination may very well protect renal and cardiac function better than either drug alone. 29, 30 The different renoprotective mechanisms of the two types of drugs support their combination.
Other drugs for hypertensive diabetics
Antidiabetic agents
In addition to chronic effects, hyperglycaemia will acutely raise blood pressure, probably by activating the renin system. Chronic hyperglycaemia clearly is involved in the development of nephropathy. To achieve adequate glycaemic control, most patients will require multiple therapies. There may be special vasodilatory effects of glitazones mediated through increased nitric oxide synthesis.
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Statins
Statins have vasodilatory effects that may be additive to those provided by ACEIs.
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Oestrogen replacement therapy (ERT)
In a small number of obese type 2 diabetics ERT (with medroxyprogesterone) was associated with reductions in waist circumference, HbA 1c , and cholesterol levels. 33 
Aspirin
In the HOT trial, aspirin (75 mg/per day) reduced major cardiovascular events by 15%, all myocardial infarction by 36%, and had no effect on stroke. 8 There were more bleeding episodes in the aspirin group but no more fatal bleeds.
Conclusion
Hypertension and diabetes commonly coexist and pose a serious threat. Fortunately, significant protection can be provided but the benefits may be hard to achieve. Health care providers must be more vigorous in applying more intensive therapy to this rapidly expanding, highly vulnerable population.
